FEELM
19.5.2022 10:43:11 CEST | Business Wire | Press release
FEELM, the flagship atomization tech brand belonging to SMOORE, today released its “Race to Zero” plan and roadmap to carbon neutrality. The plan brings forward FEELM’s ambitions to achieve net-zero carbon emissions by 2050 in its direct production activities and indirect purchased energy (scope 1&2). Meanwhile, FEELM makes a commitment that renewable energies will account for 30% of its total energy consumption by 2030.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220519005482/en/
As one of China’s first atomization tech brands to make a carbon neutrality commitment, FEELM pledges to reach net zero in full supply chain and full product lifespan by developing sustainable products, improving energy efficiency with automated production, supporting the supply chain in decarbonization, and increasing renewable energies and eco-friendly materials.
FEELM, being the world ‘s largest closed vape system solution provider, plays a significant role in the global vaping supply chain. On the one hand, it provides millions of global consumers with premium product experience by virtue of partnership with vaping brands around the world; on the other hand, FEELM has been leading a sustainable revolution in the supply chain.
Leading on Sustainability by introducing FUTURE series solutions
FEELM has been leading on sustainability and green product innovations, which is the industry’s driving force towards carbon neutrality. Committed to providing global customers with zero carbon technologies, FEELM has introduced FUTURE series solutions, which feature recyclability, disassemblability, biodegradability and minimalist design.
Since 2019, FEELM has already pioneered a number of green vaping solutions. For example, it won iF Design Award 2020 for disposable paper e-cigarette, which is made up of spiral composite paper tube, improving the degradability rate to approximately 76% of the total volume, compared with the plastic used in traditional vaping products.
Moreover, FEELM is ready to unveil another eco-friendly non-nicotine disposable e-cigarette at Vaper Expo UK 2022 in late May . This product was awarded Red Dot Awards for Product Design 2022. Its external structure is composed of recyclable and reusable aluminum foil. It looks like a paper foil pouch and itself serves as a packaging bag, hence the reduction of packaging materials.
Supporting the Global Supply Chain in Decarbonization
In addition to developing sustainable products, FEELM has also partnered with suppliers to develop and encourage utilizing biodegradable materials while optimizing the water, electricity and gas consumption management. FEELM is also working with global customers to promote the recycling and reusing, so as to explore a feasible path towards carbon neutrality for the product lifespan and the supply chain.
As a manufacturer with environmental awareness, FEELM has supported vaping brands around the world in reducing carbon footprint and empowered our customers to achieve carbon neutrality in 2050, by eliminating unnecessary plastic packaging. For example, FEELM removed single-use plastics from packaging of one of its major customers. Having removed silicone caps from e-liquid pods, it replaced all plastic tray packaging with a pulp alternate. By 2020, FEELM had already helped this customer save over 100 tons of disposable plastics, which are equivalent to 4 million plastic bottles.
To date, China has accounted for close to 90% of global production of vaping products. As the world ‘s largest closed vape system solution provider, FEELM is devoted to facilitating carbon neutrality of the whole supply chain. It has been exploring innovative, customized carbon reduction solutions along with partners, covering a full circle from raw material supply, product design, production, consumption to recycling and reusing.
FEELM has established a series of automated production lines to optimize energy efficiency. According to its in-house greenhouse gas control and water management procedures, FEELM’s greenhouse gas emissions and water consumption have decreased by 16% and 9.4% year-on-year in 2021 respectively. For example, one of FEELM’s automatic factory has saved 2.298 million kilowatts of electricity, which is equivalent to a reduction of 601 tons of carbon emissions in 2021.
Complying with International Standards, and Making Carbon Management More Transparent
Aiming for the goal that 30% of total energy consumption will come from renewable source by 2030, FEELM is also benchmarked against the standards of international organizations. In 2022, FEELM has introduced Carbon Disclosure Project (CDP) standards to its operation and production. Moving forward, FEELM plans to set up science-based emission reduction targets by submitting to Science Based Targets initiative (SBTi).
The Science Based Targets initiative (SBTi) is a collaboration established in 2015 between CDP, the United Nations Global Compact, World Resources Institute (WRI) and the World Wide Fund for Nature (WWF). By May 11, 2022, there are 2,466 companies from more than 70 countries and regions have joined the initiative, including 152 Chinese companies and one fifth of Forbes 500 companies.
“As a pioneer in going global in Chinese vaping industry, FEELM has been leveraging its full supply chain advantages and fundamental R&D in reducing carbon footprints. As China has pledged to be carbon neutral by 2060, FEELM is ready to fulfill its carbon neutral commitment to Chinese vaping industry, so as to explore a lower-carbon, greener and more sustainable development path with cutting-edge technologies,” said Frank Han, Senior Vice President of SMOORE and President of FEELM.
Moving forward, FEELM will continue to reduce the carbon footprints of vaping products by promoting the R&D and application of innovative green technologies and eco-friendly materials. In collaboration with suppliers and clients, FEELM is also committed to exploring and developing the recycling and reusing mechanism of vape pod cartridges, thereby playing a more significant role in the decarbonization of the industry.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220519005482/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
